Advertisement
ACRS 外汇新闻
Aclaris Therapeutics Says Will Discontinue Further Development Of ATI-450 Program
Biopharmaceutical company Aclaris Therapeutics, Inc. (ACRS) announced Monday top-line results from a Phase 2b study of zunsemetinib (ATI-450), an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis.
RTTNews
|
555天前
Aclaris Therapeutics, Pediatrix Therapeutics Ink License Deal For ATI-1777 In Greater China
Biopharmaceutical company Aclaris Therapeutics, Inc. (ACRS) and Chinese therapeutic company Pediatrix Therapeutics, Inc. announced that the companies have entered into a license agreement.
RTTNews
|
904天前
